New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor.

Abstract

Receptor-mediated activation of phospholipase C to generate inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] is a ubiquitous signalling pathway in mammalian systems. A family of three IP3 receptor subtype monomers form functional tetramers, which act as effectors for Ins(1,4,5)P3, providing a ligand-gated channel that allows Ca2+ ions to move between cellular compartments. As IP3 receptors are located principally, although not exclusively, in the endoplasmic reticular membrane, Ins(1,4,5)P3 is considered to be a second messenger that mobilizes Ca2+ from intracellular stores. Ca2+ store mobilization by Ins(1,4,5)P3 can be shown to contribute to a variety of physiological and pathophysiological phenomena, and therefore the IP3 receptor represents a novel, potential pharmacological target. In this article, Rob Wilcox and colleagues review recent developments in IP3 receptor pharmacology, with particular emphasis on ligand molecular recognition by this receptor-channel complex. The potential for designing non-inositol phosphate-based agonists and antagonists is also discussed.

Statistics

0102030'00'02'04'06'08'10'12'14'16
Citations per Year

80 Citations

Semantic Scholar estimates that this publication has 80 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wilcox1998NewDI, title={New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor.}, author={Robert A. Wilcox and William U Primrose and Stefan R. Nahorski and R. A. John Challiss}, journal={Trends in pharmacological sciences}, year={1998}, volume={19 11}, pages={467-75} }